One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-y (IFN-y) and tumor necrosis factor-a (TNF-a) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (/3-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-y monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy.
INTRODUCTION GENE THERAPY is a potentially important technique, permit-
ting novel approaches to the tteatment of disease (Crystal, 1995) ; however, there are limitations due to low-level and ttansient gene expression (Friedmann, 1996; Wilson, 1996) . The use of sttong, constitutive viral promoters does not usually achieve long-term ttansgene expression in vivo; and promoter extinction occurs (Scharfmann et al., 1991; Challita and Kohn, 1994; Rettinger et al., 1994) , even in the presence of substantial amounts of vector DNA in the transduced cells (Dwarki et al., 1995; Yao et al., 1996) . Using rettoviral vectors, which integrate into the host genome and theoretically result in permaDepartments of 'Surgery, ^Microbiology and Immunology, ^Pediatrics, and "Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109. nent ttansgene expression, indefinite gene expression is achieved in vitro, but only at low levels or not at all in vivo (Scharfmann et al, 1991; Rettinger et al, 1994) . The immune response to adenoviral vectors by cytotoxic T lymphocytes (CTL) is a significant limitation to vector expression (Engelhardt et al, 1994; Yang et al, 1994; Dai et al, 1995; DeMatteo et al., 1995) ; and while improved transgene expression can be achieved using less immunogenic E2 temperature-sensitive adenoviral vectors (Engelhardt et al, 1994) , immunosuppressants (Yang et al, 1994; Dai et al, 1995; DeMatteo et al, 1995; Engelhardt et al, 1994) , or immunodeficient mice (DeMatteo et al, 1995) , expression is either not permanent or is still attenuated in comparison to initial levels. These findings suggest that other factors are responsible for determining ttansferred gene expression.
It is noteworthy that immune responses may alter ttansgene expression in other ways. For example, recent studies (Tsui et al, 1995; Guidotti et al, 1996) demonsttate that in ttansgenic mice which replicate the hepatitis B vims (HBV) genome, CD8^ CTLs reduce cellular HBV mRNA by a non-cytotoxic mechanism. Analysis shows that interferon-y (IFN-y) and tumor necrosis factor-a (TNF-a), secreted by antigen-activated CTL, result in promoter-specific, post-ttanscriptional clearance of viral mRNA. These results suggest that antigen-specific or nonspecific cytokine responses initiate a series of inttacellular signals that influence transcriptional and ttanslational regulation and hence the level of ttansferred gene expression (Gribaudo et al, 1995; Harms and Splitter, 1995) . We hypothesize that cytokine-initiated signaling is a major determinant of ttansferred gene expression.
MATERIALS AND METHODS

Vectors
Viral and plasmid vectors encoding the LacZ reporter gene are shown in Table 1 . The adenoviral vectors were all generated from adenovims type 5 with an El region deletion. AdHCMV/3-gal (Csete et al, 1994) , with a human CMV immediate early 1 (HCMViel) promoter, was provided by Dr. A. Shaked (University of Pennsylvania); AdRSV/S-gal (Sttatford-Perricaudet et al, 1992) and Ad/3A/3-gal (Grossman et al, 1992) , with a Rous sarcoma vims long terminal repeat (RSV-LTR) and /3-actin promoter plus CMV enhancer, respectively, were obtained from the vector core of the University of Michigan Medical Center. There may be uncharacterized differences other than promoter regions among these vectors because they were constmcted by in vivo homologous recombination in different laboratories. Plasmid vectors: pMP6A)3-gal (Philip et al, 1994) with HCMViel promoter was provided by Dr. M. Philip (Applied Immune Sciences Inc., Santa Clara, CA); pRSV)3-gal (Gorman et al., 1982) with RSV-LTR was provided by Dr. G. Warr (Medical University of South Carolina); pCHllO (Hall et al, 1983) with SV40 promoter was purchased from Pharmacia (Piscataway, NJ). Rettoviral vector MGFLacZ (Tahara et al, 1992) with the Moloney murine leukemia vims long terminal repeat (MMLV-LTR) promoter was provided by Dr. H. Tahara (University of Pittsburgh).
Reporter gene expression and cytotoxicity assay C2C12 myoblasts (Yaffe and Saxel, 1977) were infected with adenoviral vectors at a multiplicity of infection (moi) of 10-100 for 20 hr (which resulted in >75% of cells expressing the PGal activity determined by X-Gal staining), or transfected with 2 p.g of plasmid per 5X10^ cells by 30 /xg of Lipofectamine Reagent (GIBCO-BRL, Grand Island, NY) in semm-free OPTI-MEM (GIBCO-BRL) for 5 hr (which resulted 5-10% of cells expressing /3-Gal determined by X-Gal staining), or infected with a retroviral vector at a moi of 2 in the presence of 8 /xg/ml of Polybrene for 20 hr (which resulted in >50% cells expressing /3-Gal determined by X-Gal staining). Cells were then trypsinized, replated at 1 X lO^'-l X 10^ cells/cm^, exposed to IFN-y and/or TNF-a at various doses for 24-72 hr, and assayed for /3-Gal activity, total cellular protein, and cell viability. The ;S-Gal activity was determined by c>-nittophenyl-/3-D-galactopyranoside (ONPG) assay kit (Sttatagene, La Jolla, CA), the total cellular protein was determined by Bradford assay (BioRad, Hercules, CA), cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltettazolium bromide (MTT) (Sigma, St. Louis, MO) assay (Mosmann, 1983) , cell proliferation was determined by [^H] thymidine incorporation, and the cell cycle was assayed by propidium iodide (PI) (Sigma) assay (Noguchi, 1996) . All assays samples were performed in triplicate and experiments repeated at least three times.
Northern and Southern blots C2C12 myoblasts were infected with adenoviral vectors and treated with cytokines as described above. The cells were lysed, and RNA and DNA were isolated separately (Trizol reagent, GIBCO-BRL, Grand Island, NY). The RNA was mn on a 1% formaldehyde gel and transferred to a nylon membrane (BioRad, Hercules, CA). The DNA was denatured with 0.2 N NaOH and loaded on a nylon membrane. Hybridization was performed (Hall et al, 1983 ); the ;8-actin probe was a 540-bp polymerase chain reaction (PCR) product between base pairs 25 and 565 generated from C57BL/6 genomic DNA (Alonso et al, 1986) ; the GAPDH probe was a 294-bp reverse ttanscription (RT)-PCR product between base pairs 309 and 602 generated from C57BL/10J lymphocytes (Sabath et al, 1990) . For Southem blotting of cardiac allografts, whole transplanted hearts were explanted, homogenized in Trizol, DNA isolated, restricted with Bam HI, and Southem blotted with [32p]dCTP random primerlabeled /3-Gal probe for a 4-kb adenoviral fragment.
Western blot
Lysates from the tteated cells were mn on a 7.5% SDS-PAGE, transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA), blotted with a mouse monoclonal antibody (mAb) specific for adenovims 72K DNA binding protein (Reich et al, 1983) , and horseradish peroxidase (HRP)-coupled sheep anti-mouse immunoglobulin G (IgG) (Amersham, Arlington Heights, IL). The signal was detected by using the ECL Westem blotting system (Amersham) and exposure to X-ray film.
P-Ga/ expression in a murine heterotopic, nonvascularized cardiac transplantation model Donor neonatal C57BL/6 mice (Harlan-Sprague-Dawley, Inc., Indianapolis, IN) were sacrificed, and whole hearts were removed and placed in a subcutaneous (s.c.) position of the ear pinnae of C57BL/6 recipients (Qin et al, 1996) Five X 10'' pfu of AdHCMV;8-gal or AdRSV/3-gal in 5 /xl was directly injected into the graft at the time of ttansplantation. Anti-IFN-y mAb (R4-6A2) (Spitalny and Havell, 1984) and isotype-matched conttol mAb Y13-259 (Furth etal, 1982) hybridomas were purchased from the American Type Culmre Collection (ATCC;
Rockville, MD) and grown in culture; the culmre supematant was purified over protein G columns (Pharmacia-LKB, Piscataway, NJ). Purified mAbs were injected intravenously (i.v.) at 100 /xg every other day for six doses. The ears with ttansplanted hearts were harvested at various time points after ttansplantation, quick frozen, embedded in O.C.T. (Miles Scientific, Naperville, IL), sectioned at 10 /xm, collected onto gelatincoated glass slides, fixed at room temperature in 0.25% glutaraldehyde m phosphate-buffered saline (PBS) for 30 min, rinsed three times in PBS for a total of 30 min, and incubated at 37°C ovemight m 0.5 mg/ml 5-bromo-4-chloro-3-indolyl-/8-D-galactopyranoside (X-Gal) solution containing 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mAf MgC^, 1 mM spermidine, 0.02% Nonidet P-40, and 0.01% sodium deoxycholate in PBS. After staining, the sections were fixed with 4% formaldehyde and counterstained with eosin (Qin et al, 1996) . Quantitative assay of inttagraft reporter gene expression was performed using the luminescent /3-Gal detection kit II (Clontech, Palo Alto, CA) according to the manufacturer's recommendations.
RESULTS
IFN-y and TNF-a inhibit adenoviral vector reporter gene expression without killing transduced cells
To test whether cytokine-mediated signals could alter vector gene expression, resulting in gene attenuation or extinction, C2C12 myoblasts were infected with adenoviral vectors encoding the LacZ reporter under the conttol of HCMViel (AdHCMV/3-gal), RSV-LTR (AdRSV/3-gal), or /3-actin (AdjSA/3-gal) promoters, exposed to 30 U/ml of IFN-y and/or TNFa for 24 hr and assayed for j8-Gal activity, total cellular protein, cell viability, cell proliferation, and cell cycling. The results in Table 2 demonstrate that viral promoters (HCMViel and RSV-LTR) were sensitive to the inhibitory effects of the C2C12 myoblasts were infected with indicated adenoviral vectors for 20 hr (which resulted in >75% of cells expressing the /3-Gal activity determined by X-Gal staining), the cells were then exposed to 30 U/ml of IFN-y and/or TNF-a for 24 hr, and assayed for j8-Gal activity (expressed as units per mg of cellular protein) and total cellular protein (expressed as mg per milliliter of cell lysate from 2 X 10* infected C2C12). The experiment was performed six times with similar results.
cytokines, compared to the cellular promoter (/3-actin). There was a slight inhibitory effect on the /3-actin promoter by IFNy but not by TNF-a. It should be noted that this particular jSactin promoter constmct also contained a CMVie enhancer (Grossmann et al, 1992) . Nonetheless, it was anticipated that a housekeeping gene promoter would be less sensitive to the regulatory effects of cytokines. Despite inhibition of /3-Gal activity, total cellular protein was unaffected (Table 2) , and there were no changes in cell viability, proliferation, and cycling ( Fig.  1) , showing that the cytokines did not have global inhibitory effects on basic cellular functions. Additional experiments showed that while IFN-y and TNF-a had inhibitory effects on reporter expression, other cytokines, including pro-inflammatory cytokines [interieukin-1 (IL-1), IL-6, and TGF-/3], THI cytokines (IL-2 and IL-12), TH2 cytokines (IL-4 and IL-10), and chemokines [macrophage inhibitory protein-la (MIP-la), MIP 1/3, MIP2, and KC] did not, even at high doses (not shown).
IFN-y and TNF-a synergistically inhibit reporter gene expression from viral but not cellular promoters More detailed dose-response analyses demonsttated that the HCMViel promoter was sensitive to the inhibitory effects of high concenttations of IFN-y and very sensitive to even low doses of TNF-a. The RSV-LTR promoter was generally very sensitive to IFN-y and less sensitive to TNF-a inhibitory effects. The /3-actin promoter showed some sensitivity to only high concenttations of either IFN-y or TNF-a ( Fig. 2A,B) . Whereas the /3-actin and HCMViel promoters appear to have similar sensitivities to high concenttations of IFN-y ( Fig. 2A) , differences are readily apparent at lower, physiologically relevant concenttations (Table 2 ; Fig. 2C ). Importantly, the combination of IFN-y plus TNF-a had marked synergistic inhibitory effects on the HCMViel and RSV-LTR promoters, but none did on the /3-actin promoter (Fig. 2C) . We conclude that IFN-y and TNF-a initiate marked inhibitory and synergistic effects on selected viral promoters (HCMViel, RSV-LTR) but not on a cellular promoter (/3-actin) in adenoviral gene ttansfer vectors.
IFN-y and TNF-a inhibit transgene expression at mRNA level without degrading viral DNA To understand the level at which cytokines regulate reporter protein expression, Northem blotting was performed on cytokinetteated cells and showed that IFN-y plus TNF-a synergistically decreased the level of /3-Gal mRNA by about 60% from the HCMViel and RSV-LTR promoters, whereas they had much less effect on the /3-actin promoter (Fig. 3A) . It is interesting to note that EFN-y and TNF-a had a similar magnitude of effect on reporter activity and mRNA expression (compare the percent in- 5X10^ C2C12 cells were ttansfected with 2 p,g of indicated plasmids encoding the LacZ reporter by 30 ;u,g of Lipofectamine Reagent (GIBCO-BRL, Grand Island, NY) in semm-free OPTI-MEM (GIBCO-BRL, Grand Island, NY) for 5 hr, treated with 30 U/ml of IFN-y and/or TNF-a for 24 hr, and assayed as described. The experiment was performed three times with similar results. hibition in Table 2 versus Fig. 3A ). This suggests that mRNA ttanscription is a major locus of conttol of gene expression by these cytokines. Southem blot analysis of vector DNA from these cells showed no difference among the groups (not shown). This suggests that IFN-y and TNF-a are not activating cellular mechanisms that degrade the vector genome or otherwise rid the cells of the vector DNA. Lysates from these same cells were analyzed by Westem blotting for the 72K DNA binduig protein of adenovims. The 72K DNA binding protein is normally expressed by these El-deleted adenoviral vectors, conttolled by the adenoviral E2 promoter 27 kb downstteam from the reporter, and ttanscribed from the linear DNA genome in the opposite direction from the reporter gene (Reich et al, 1983) . The Westem blotting results (Fig. 3B ) demonsttated that IFN-y had no effect on 72K DNA binding protein expression, whereas TNF-a decreased expression by about 30% and the combined IFN-y plus TNF-a tteatment decreased expression by about 45%. This shows that cytokines may affect not only gene expression conttolled by the HCMViel promoter but also expression of other genes on the same adenoviral genome. Because the cytokine effects on reporter activity and on 72K DNA binding protein expression are not the same (compare the percent inhibition in Fig. 3B versus Table 2 and the effect of IFN-y versus TNF-a), diis suggests that cytokines initiate signals that regulate different viral promoters in a promoter-specific fashion.
IFN-y and TNF-a inhibit transgene expression delivered by plasmid and retroviral vectors
To determine if these cytokine inhibitory effects were associated only with adenoviral vectors or could be observed with other vectors, C2C12 cells were transfected with plasmid DNA encoding the LacZ reporter, or infected with a retroviral vector encoding LacZ, treated with IFN-y and/or TNF-a, and assayed as described above. The results in Table 3 demonstrate that IFNy and TNF-a were able to inhibit plasmid reporter expression from HCMViel, RSV-LTR, and SV40 promoters and did so in an additive or synergistic fashion. These results are qualitatively similM to those with adenoviral vectors, and controls likewise showed no effect on cell viability or proliferation (not shown). IFN-y and TNF-a also inhibited reporter gene expression from tiie retroviral vector MFG-LacZ with the MMLV-LTR promoter (Table 4) . Transgene expression could be restored two days after these cytokines were removed from culture (Table  4) , which again indicates that inhibition of gene expression is at the ttanscriptional and/or ttanslational level and that cytokines do not cause vector nucleic acid degradation or kill ttansduced cells. These results further support the hypothesis that cytokine-initiated events are acting at the level of ttanscriptional control and do not involve other vector or vims-specific loci or mechanisms.
Anti-IFN-y mAb prolongs adenoviral vector reporter gene expression in vivo
To determine if cytokine manipulation was also relevant for the expression of ttansferred genes in vivo, syngeneic cardiac ttansplants were performed using C57BL/6 donor hearts and recipient mice. The operative trauma and ischemic injury to the graft result in tissue damage and immunologically nonspecific generation of cytokines such as IFN-y. The grafts were each injected with the viral vector AdHCMV/3-gal. Recipients were also untreated or treated with anti-IFN-y mAb or an isotypematched control mAb, grafts harvested at various time points after ttansplantation, and frozen sections stained with X-Gal for ^-Gal activity. The treatment with adenoviral vectors or mAbs did not affect the survival of tiie syngeneic grafts as determined by electtocardiogram (EKG) verification (not shown). The results in Fig. 4 , however, demonsttate that anti-IFN y mAb treatment resulted in more prolonged and higher level /3-Gal expression, as detennined by X-Gal staining, to at least 30 days after transplantation, suggesting enhanced reporter gene expression as a result of neutralizing IFN-y with specific mAb.
Similar results were observed using a quantitative /3-Gal assay. Reporter gene expression from AdRSV/3-gal could be prolonged by anti-IFN-y mAb (Fig. 5) to a level 10 times higher 6.7 C2C12 cells were infected with a rettoviral vector MFG-LacZ at moi of 2 in the presence of 8 mg/ml of Polybrene (which resulted >50% cells expressing ;S-Gal determined by X-Gal staining). Transduced cells were treated with 30 U/ml of IFN-y and/or TNF-a for (I) 20 hr, (II) 3 days, and (III) 20 hr followed by washing and incubation for an additional 2 days, and assayed as described. The experiment was performed three times with similar results. than control. These results are commensurate with those obtained with the C2C12 myoblast line in vitro.
It is possible that these results could be explained not only by differences in promoter function as a result of neutralizing IFN-y with specific mAb, but also by inhibition of anti-adenoviral vector immunity and cytotoxicity by the mAb. To address this issue, grafts were harvested 10 days after fransplantation, a time at which there was a large difference in X-Gal staining between conttol and treated groups, as shown in Fig.  4 . DNA was isolated, digested with Bam HI, and Southem blotted with the /3-Gal probe. The results demonstrate no difference between the groups in the amount of vector DNA in the cardiac tissues (Fig. 6 ). This suggests that the difference in reporter expression is due to the effects of promoter activity on gene transcription and not due to the specific immune response killing infected cells, which would have caused a decrease in vector DNA and affected syngeneic graft survival, neither of which effects were observed.
DISCUSSION
The data here indicate that the cytokines IFN-y and TNF-a inhibit transgene expression from certain widely used viral promoters (CMV, RSV, SV40, MMLV-LTR) delivered by adenoviral, retroviral, or plasmid vectors in vitro. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. It is possible that these cytokine effects have not generally been noted previously because most work has been performed in vitro under conditions of low and unchanging cytokine concentrations. These results have significant implications for the constmction of transfer vectors because there are at least three situations in which gene transfer vectors could be exposed to a cytokine-rich environment when they are administered ;/; vivo: (i) Gene therapy has been considered for the treatment of diseases {e.g., cancer, AIDS, transplantation, atherosclerosis, autoimmunity, ischemia-reperfusion) (Crystal, 1995) , which have in common the ubiquitous production of cytokines through either antigen-specific stimulation of lymphocytes, or nonspecific stimulation of lymphocytes, other leukocytes, vascular endothelial cells, or organ parenchymal cells by infection, ischemia, necrosis, or trauma. The grafts were explanted after 10 days, and Southem blotting for /3-Gal was performed on adenoviral genomic DNA isolated from the cardiac tissues. DeMatteo et al, 1995; Krieg el al, 1995; Sato et al, 1996) . For example, recombinant adenoviruses stimulate host immune responses which involve IFN-y and IL-2 (Engelhardt et al., 1994; Yang et al, 1994; Dai et al, 1995; DeMatteo el al, 1995) . In addition, the transferred nucleic acids themselves are capable of inducing several cytokines including IFN-a, 1FN-/3, IL-12, and IFN-y (Krieg et al, 1995; Sato et al, 1996) . Despite the fact that cytokines are likely to be frequently present during gene therapy applications and influence cellular responses, there are few studies in the current gene therapy literature that examine the effects of cytokine signals on the transcriptional and translational disposition of transferred genes (Harms and Splitter, 1995) . Instead, the cellular targets of gene transfer vectors and the other physiologic signals impinging on these cells have often been considered passive participants in the process of gene transfer and expression. It is notable that the CMVie, RSV, SV40. and MMLV-LTR promoters and enhancers, which are cytokine sensitive as shown here, are widely used in gene transfer vectors. Thus, vectors in current use may not be entirely appropriately constmcted to provide for sustained gene expression because the cytokine environment or the gene transfer product itself may inhibit its own promoter. For example, IFN-y and TNF-a have been transduced into tumor cell lines or tumor-infiltrating lymphocytes by retroviral vectors with the MMLV-LTR promoter (Karp et al, 1993; Marincola el al. 1994 ). Much of the work has focused on characterizing short-term gene expression of cells transduced in vitro rather than evaluating chronic gene expression in conjunction with potential antitumor activity ;>; vivo. In fact, genetically modified, TNF-a-secreting, nonimmunogenic murine fibrosarcomas failed to elicit a host immune response, which is in contrast to tbe effects with an IL-2-secreting tumor (Karp et al, 1993) . In other applications of gene therapy, retroviral vectors are used to transduce bone marrow stem cells, which are then expanded in the presence of growth factors, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF). stem cell factor (SCF), lL-3, lL-6, and lL-7 (Lu et al. 1993 ). yet the effects of these growth factors on viral promoters or other promoters have not been investigated.
In an attempt to enhance the efficacy of a plasmid DNA vaccine to rabies virus, cytokine-expressing plasmids (IFN-y and GM-CSF) were co-inoculated with the viral antigen encoding plasmid under the control of the SV40 eariy promoter. The GM-CSF-expressing plasmid increased antiviral immunity by stimulating both the antibody and the T helper cell responses. Conversely, an IFN-y-expressing plasmid had no such immunostimulatory effects, but rather resulted in a slight decrease in antibody and cytokine production (Xiang and Ertl, 1995) . This unanticipated effect of IFN-y could be due to inhibition of the SV4() early promoter by IFN-y, so that less viral antigen was produced when the plasmid was co-injected with IFN-yexpressing plasmid. T lymphocytes are particulariy recalcitrant to attempts at stable gene transfer and expression (Rosenberg, 1991; Chu cl al. 1992) . Because these cells are immunologically active, and in particular produce IFN-y and TNF-a, the results presented here may provide a partial explanation for this resistance. It should also be noted that these and other cytokines can activate these viral promoters under other circumstances (Tzen and Scott, 1993; Stein et al, 1993; Fietze et al, 1994; John et al, 1994 Laegreid et al, 1994 ; and that these promoters can occasionally direct long-term gene expression in vivo, even in immunocompetent recipients (Barr et al, 1995; Poller et al, 1996) .
It is well known that IFNs, produced by vims-infected cells as part of the innate immune system, can signal to neighboring cells to resist viral replication and prevent vims spread (Samuel, 1991; Farrar and Schreiber, 1993) . TNF-a is also a potent antiviral cytokine that acts alone or in a synergistic manner with IFN-y to protect cells from viral infection (Wong et al, 1986 (Wong et al, , 1992 Wietzerbin et al, 1990) . A number of studies suggest that these cytokines are basic cellular defenses against viral nucleic acids and that cells can distinguish viral from cellular sequences. For example, it has been reported that IFN-y and IFNa can inhibit the transcription of murine cytomegalovims (MCMV) immediate-early genes (Gribaudo et al, 1995) . The inhibitory effect on MCMVie gene enhancer function is related at least partially to cytokine-induced inhibition of NF-/<B activity (Gribaudo et al, 1995) . It is likely that NF-kB activity is directly inhibited by the p202 protein, which is induced by IFNy and which direcdy binds to and inhibits the function of the p50 and p65 subunits of NF-kB (Wang et al, 1996) . p202 can also bind to and inhibit the c-fos and c-jun subunits of the AP-1 ttanscription factor (Wang et al, 1996) , which may have negative regulatory effects because AP-1 binding sites have been mapped inside the MCMV promoter/enhancer region (Gribaudo et al, 1995) . Because p202 inhibits cell cycling and proliferation, it is probably not mediating the effects observed in the present report because the cytokines did not affect C2C12 proliferation. A more recent report shows that IFN-y-induced STATl competes for the CBP and p300 co-activator proteins, and thereby inhibits AP-1 and ets-dependent transcriptional activation (Horvai et al, 1997) . There is also recent evidence that Kupfer cells, known producers of IFN-y and TNF-a, play a role in immunologically nonspecific elimination of adenoviral vectors in the liver following in vivo administtation (Worgall et al., 1997) . Inhibition of early viral promoters, as shown here, provides an additional mechanism for the antiviral effects of IFNs and TNF-a. Determination of the mechanisms involved in cytokine-regulated gene expression and a comprehensive understanding of promoter cytokine sensitivities may significantiy alter the design of vectors for gene ttansfer and gene therapy.
